Table 6.
Study | N | Design | Dosage (mg) | Duration (weeks) | Pre-tx IELT (sec) | Post-tx IELT (sec) | Mean change (sec) | Fold increase |
---|---|---|---|---|---|---|---|---|
Safarinejad (2006) [219] | 64 | RCT, placebo, blinded | 50 | 8 | 19 | 243 | 224 | 13 |
Salem (2008) [222] | 60 | Crossover, placebo, blinded | 25 | 8 | 70 | 442 | 372 | 6.3 |
Alghobary (2010) [221] | 35 | Crossover, comparison (paroxetine) | 50 | 12 | 36 | 180, 133 | 144, 97 | 7.3, 5.7 |
Kaynar (2012) [175] | 60 | Crossover, placebo, blinded | 25 | 8 | 39 | 155 | 116 | 4 |
Bar-Or (2012) [223] | 604 | RCT, placebo, blinded | 62, 89 | 12 | 58 | 134, 151 | 76, 93 | 2.4, 2.5 |
Eassa (2013) [224] | 300 | Randomized, dose response | 25, 50, 100 | 24 | 174 | 790, 1,405, 2,189 | 616, 1,231, 2,015 | 4.5, 8.1, 12.6 |
RCT = randomized controlled trial; tx = treatment